COMPANY PROFILE // THE 014 REPORT
Regeneron Pharmaceuticals, Inc.
REGN (Nasdaq)
Assembled from 6 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- InfoGLEIF: no direct parent reported; reporting exception reason NO_KNOWN_PERSON.
✓ SEC filings✓ LEI✓ State registrationpossible match✓ Lobbying registrationpossible match✗ SAM registration✗ IRS return✗ Website
No SAM registration, no IRS return, no website on record.
REGENERON PHARMACEUTICALS, INC. is an SEC-registered operating company in pharmaceutical preparations, incorporated in NY, based in Tarrytown, NY; listed as REGN (Nasdaq).[source] It reported revenue of $14.34 billion for the fiscal year ended 2025-12-31.[source] It has filed 104 documents with the SEC in the last 12 months; the latest is a S-8, filed 2026-11-19.[source] 8 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC, Dodge & Cox (as of 2026-06-30).[source] 22 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]
- red0
- amber0
- info1
- BlackRock, Inc.$5.68B
- VANGUARD CAPITAL MANAGEMENT LLC$4.13B
- Dodge & Cox$3.04B
- STATE STREET CORP$3.01B
- Invesco Ltd.$2.46B
- JPMORGAN CHASE & CO$2.38B
- VANGUARD PORTFOLIO MANAGEMENT LLC$1.98B
- FRANKLIN RESOURCES INC$1.73B
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. (Wikipedia, CC BY-SA 4.0)
Officers and directors (Forms 3, 4, 5)
- Fenimore Christopher R. · EVP Finance CFO (Officer) · latest Form 4 2025-12-09 · filing · LinkedIn search
- LAROSA JOSEPH J · EVP General Counsel and Secret (Officer) · latest Form 4 2025-12-09 · filing · LinkedIn search
- MURPHY ANDREW J · EVP Research (Officer) · latest Form 4 2025-12-11 · filing · LinkedIn search
- McCourt Marion · EVP Commercial (Officer) · latest Form 4 2025-12-11 · filing · LinkedIn search
- Pitofsky Jason · SVP Controller (Officer) · latest Form 4 2026-02-11 · filing · LinkedIn search
- SCHLEIFER LEONARD S · Bd. Co-Chair, President & CEO (Director,Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Van Plew Daniel P · EVP & General Mgr, Industrial (Officer) · latest Form 4 2025-12-11 · filing · LinkedIn search
- YANCOPOULOS GEORGE · Bd. Co-Chair, President & CSO (Director,Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- BROWN MICHAEL S · Director · latest Form 4 2026-01-06 · filing · LinkedIn search
- Bassler Bonnie L · Director · latest Form 4 2026-01-08 · filing · LinkedIn search
- COLES N ANTHONY · Director · latest Form 4 2026-01-06 · filing · LinkedIn search
- GOLDSTEIN JOSEPH L · Director · latest Form 4 2026-01-06 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Links
- Official website (Wikidata or the SEC record)
- Wikipedia
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 22 CLEAR, 4 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0000872589 | source |
| LEI | 549300RCBFWIRX3HYQ56 | source |
| EIN | 13-3444607 | source |
| NY DOS ID | 1226128 | record |
| California SOS entity | 0471116-01-999-0471116 | record |
| Connecticut business ID | 1054405 | record |
| LDA clientpossible match | 67618 | record |
| LDA clientpossible match | 65271 | record |
| LDA clientpossible match | 64079 | record |
| Business address (SEC) | 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591 | source |
Does not exist in the records we hold: UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2026-12-01 · in 10 days · LEI next renewal (549300RCBFWIRX3HYQ56)
- 2027-03-01 · in 100 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 170 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Royalty Pharma plc · Bassler Bonnie L
- SHERWIN WILLIAMS CO · POON CHRISTINE A
- NEUROCRINE BIOSCIENCES INC · POON CHRISTINE A
- PRUDENTIAL FINANCIAL INC · POON CHRISTINE A
- Denali Therapeutics Inc. · Schenkein David P
- Prime Medicine, Inc. · Schenkein David P
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · Thompson Craig B.
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-19 filing S-8 · SEC EDGAR
- 2026-11-17 filing 144 · SEC EDGAR
- 2026-11-17 filing 144 · SEC EDGAR
- 2026-11-16 filing 144 · SEC EDGAR
- 2026-11-16 filing 144 · SEC EDGAR
- 2026-11-04 filing 144 · SEC EDGAR
- 2026-11-04 filing 144 · SEC EDGAR
- 2026-11-03 filing 144 · SEC EDGAR
- 2026-11-02 filing 144 · SEC EDGAR
- 2026-11-02 filing 144 · SEC EDGAR
- 2026-11-02 filing 144 · SEC EDGAR
- 2026-10-30 filing 144 · SEC EDGAR
- 2026-10-30 filing 144 · SEC EDGAR
- 2026-10-30 filing 144 · SEC EDGAR
- 2026-10-30 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-30 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-14 filing 144 · SEC EDGAR
- 2026-10-06 filing 8-K items 1.01,2.02,8.01 · SEC EDGAR
- 2026-09-30 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-09-03 filing 144 · SEC EDGAR
- 2026-09-02 filing 144 · SEC EDGAR
- 2026-09-02 filing 144 · SEC EDGAR
- 2026-08-20 filing N-PX · SEC EDGAR
- 2026-08-10 filing 144 · SEC EDGAR
- 2026-08-10 filing 144 · SEC EDGAR
- 2026-07-30 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-30 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-06 filing 8-K items 2.02 · SEC EDGAR
- 2026-07-02 filing 144 · SEC EDGAR
- 2026-06-17 filing 8-K items 5.07 · SEC EDGAR
157 earlier entries
- 2026-04-29 filing Quarterly report (10-Q)
- 2026-04-29 filing 8-K items 2.02,9.01
- 2026-04-24 filing ARS
- 2026-04-24 filing DEFA14A
- 2026-04-24 filing Proxy statement
- 2026-04-08 filing 8-K items 2.02
- 2026-02-19 filing 144
- 2026-02-09 filing 144
- 2026-02-09 filing 144
- 2026-02-04 filing Annual report (10-K)
- 2026-01-30 filing 8-K items 2.02,9.01
- 2026-01-12 filing 8-K items 2.02,7.01,9.01
- 2026-01-07 filing 144
- 2026-01-06 insider First Form 3/4/5 on record for BROWN MICHAEL S (Director)
- 2026-01-06 insider First Form 3/4/5 on record for COLES N ANTHONY (Director)
- 2026-01-06 insider First Form 3/4/5 on record for GOLDSTEIN JOSEPH L (Director)
- 2026-01-06 insider First Form 3/4/5 on record for Guarini Kathryn (Director)
- 2026-01-06 insider First Form 3/4/5 on record for RYAN ARTHUR F (Director)
- 2026-01-06 insider First Form 3/4/5 on record for Schenkein David P (Director)
- 2026-01-06 insider First Form 3/4/5 on record for Thompson Craig B. (Director)
- 2026-01-06 insider First Form 3/4/5 on record for Zoghbi Huda Y (Director)
- 2025-12-31 insider First Form 3/4/5 on record for SING GEORGE L (Director)
- 2025-12-11 insider First Form 3/4/5 on record for SCHLEIFER LEONARD S (Bd. Co-Chair, President & CEO)
- 2025-12-11 insider First Form 3/4/5 on record for YANCOPOULOS GEORGE (Bd. Co-Chair, President & CSO)
- 2025-12-09 insider First Form 3/4/5 on record for Fenimore Christopher R. (EVP Finance CFO)
- 2025-12-09 insider First Form 3/4/5 on record for McCourt Marion (EVP Commercial)
- 2025-12-09 insider First Form 3/4/5 on record for Van Plew Daniel P (EVP & General Mgr, Industrial)
- 2025-11-24 insider First Form 3/4/5 on record for LAROSA JOSEPH J (EVP General Counsel and Secret)
- 2025-11-24 insider First Form 3/4/5 on record for Bassler Bonnie L (Director)
- 2025-11-20 filing 144
- 2025-11-10 insider First Form 3/4/5 on record for Pitofsky Jason (SVP Controller)
- 2025-11-07 filing 144
- 2025-10-31 insider First Form 3/4/5 on record for MURPHY ANDREW J (EVP Research)
- 2025-10-31 insider First Form 3/4/5 on record for POON CHRISTINE A (Director)
- 2025-10-29 filing 144
- 2025-10-28 filing Quarterly report (10-Q)
- 2025-10-28 filing 8-K items 2.02,9.01
- 2025-10-06 filing 8-K items 2.02
- 2025-08-01 filing Quarterly report (10-Q)
- 2025-08-01 filing 8-K items 2.02,9.01
- 2025-06-18 filing 8-K items 5.07
- 2025-04-29 filing Quarterly report (10-Q)
- 2025-04-29 filing 8-K items 2.02,9.01
- 2025-04-29 filing ARS
- 2025-04-29 filing DEFA14A
- 2025-04-29 filing Proxy statement
- 2025-04-17 filing UPLOAD
- 2025-04-07 filing PRE 14A
- 2025-04-03 filing CORRESP
- 2025-03-21 filing UPLOAD
- 2025-02-05 filing Annual report (10-K)
- 2025-02-04 filing 8-K items 2.02,8.01,9.01
- 2025-01-13 filing 8-K items 2.02,7.01,9.01
- 2024-11-01 filing 144
- 2024-10-31 filing S-3ASR
- 2024-10-31 filing Quarterly report (10-Q)
- 2024-10-31 filing 8-K items 2.02,9.01
- 2024-10-07 filing 8-K items 2.02
- 2024-10-01 filing 144
- 2024-09-11 filing UPLOAD
- 2024-09-03 filing 144
- 2024-08-28 filing 144
- 2024-08-15 filing 144
- 2024-08-15 filing 144
- 2024-08-14 filing 144
- 2024-08-08 filing 144
- 2024-08-07 filing 144
- 2024-08-02 filing 144
- 2024-08-01 filing CORRESP
- 2024-08-01 filing 144
- 2024-08-01 filing 144
- 2024-08-01 filing Quarterly report (10-Q)
- 2024-08-01 filing 8-K items 2.02,9.01
- 2024-07-22 filing UPLOAD
- 2024-07-08 filing 8-K items 2.02
- 2024-07-01 filing 144
- 2024-06-24 filing 144
- 2024-06-20 filing 8-K items 5.07
- 2024-06-14 filing 144
- 2024-06-12 filing 144
- 2024-06-06 filing 144
- 2024-06-05 filing 144
- 2024-06-03 filing 144
- 2024-05-28 filing 144
- 2024-05-21 filing 144
- 2024-05-20 filing CORRESP
- 2024-05-15 filing 144
- 2024-05-14 filing 144
- 2024-05-09 filing UPLOAD
- 2024-05-02 filing Quarterly report (10-Q)
- 2024-05-02 filing 8-K items 2.02,9.01
- 2024-05-01 filing 144
- 2024-05-01 filing 144
- 2024-04-25 filing ARS
- 2024-04-25 filing DEFA14A
- 2024-04-25 filing Proxy statement
- 2024-04-01 filing 144
- 2024-03-14 filing 144
- 2024-03-01 filing 144
- 2024-02-26 filing 144
- 2024-02-26 filing 144
- 2024-02-26 filing 144
- 2024-02-23 filing 144
- 2024-02-22 filing 144
- 2024-02-22 filing 144
- 2024-02-14 filing 144
- 2024-02-09 filing 144
- 2024-02-09 filing 144
- 2024-02-08 filing 144
- 2024-02-08 filing 144
- 2024-02-07 filing 144
- 2024-02-07 filing 144
- 2024-02-07 filing 144
- 2024-02-05 filing 144
- 2024-02-05 filing Annual report (10-K)
- 2024-02-02 filing 8-K items 2.02,9.01
- 2024-02-01 filing 144
- 2024-02-01 filing 144
- 2024-01-31 officer change 8-K items 5.02
- 2024-01-30 filing 144
- 2024-01-23 filing 144
- 2024-01-08 filing 8-K items 2.02,7.01,9.01
- 2024-01-03 filing 144
- 2024-01-02 filing 144
- 2024-01-02 filing 144
- 2024-01-02 filing 144
- 2023-12-27 filing 144
- 2023-12-21 filing 144
- 2023-12-13 filing 144
- 2023-12-11 filing 144
- 2023-12-05 filing 144
- 2023-11-14 filing 144
- 2023-11-07 filing 144
- 2023-11-02 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 2.02,9.01
- 2023-11-01 filing 144
- 2023-10-13 filing 144
- 2023-10-05 filing 8-K items 2.02
- 2023-10-03 filing 144
- 2023-10-02 filing 144
- 2023-09-27 filing SC 13D/A
- 2023-09-25 filing SC TO-T/A
- 2023-09-12 filing SC TO-T/A
- 2023-09-08 filing 8-K/A items 5.07
- 2023-09-08 officer change 8-K items 5.02
- 2023-09-08 filing SC TO-T/A
- 2023-09-01 filing 144
- 2023-08-25 filing SC TO-T
- 2023-08-24 filing 144
- 2023-08-23 filing 144
- 2023-08-23 filing 144
- 2023-08-22 filing 144
- 2023-08-21 filing 144
- 2023-08-18 filing SC 13D
- 2023-08-10 filing 144
- 2023-08-09 filing SC TO-C
- 2019-06-19 name change Name changed from REGENERON PHARMACEUTICALS INC
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-19 (within 7 days) S-8 filed (FORM S-8)
- 2026-11-05 (within 30 days) 13F-HR filed
- 2026-10-30 (within 30 days) 10-Q filed
- 2026-10-30 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-13 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-10-06 (older) 8-K filed: Item 1.01 material agreement; Item 2.02 results of operations; Item 8.01 other event
- 2026-10-05 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-09-30 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:REGN The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
29 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 872589 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | REGN / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI | 335800DYBVNUYLGVHJ55 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 335800DYBVNUYLGVHJ55) | GLEIF |
| LEI | 635400NABUOXXFAMHX81 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 635400NABUOXXFAMHX81) | GLEIF |
| LEI (root of the ownership tree) | 549300RCBFWIRX3HYQ56 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300RCBFWIRX3HYQ56) | GLEIF |
| EIN | 133444607 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000872589 | SEC EDGAR / IRS |
| CUSIP | 75886F107 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000872589 | SEC EDGAR |
| UEI | N3F9MH7E6HD6 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000872589 | USAspending |
possible match: matched by name only, not merged (14)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| LDA client id | 65271 (REGENERON PHARMACEUTICALS INC. (lobbying via CHECKMATE GOVERNMENT RELATIONS)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 200807 (REGENERON PHARMACEUTICALS, INC (lobbying via REGENERON PHARMACEUTICALS, INC)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 210738 (REGENERON PHARMACEUTICALS, INC. (lobbying via ARNOLD & PORTER KAYE SCHOLER LLP)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 67618 (REGENERON PHARMACEUTICALS, INC. (lobbying via BGR GOVERNMENT AFFAIRS)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 208641 (REGENERON PHARMACEUTICALS, INC. (lobbying via STEWART STRATEGIES AND SOLUTIONS, LLC)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 64079 (REGENERON PHARMACEUTICALS, INC. (lobbying via THE WASHINGTON TAX & PUBLIC POLICY GROUP)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 196249 (REGENERON PHARMACEUTICALS, INC. (lobbying via an individual registrant)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 162758 (REGENERON PHARMACEUTICALS, INC. (lobbying via an individual registrant)) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | Lobbying Disclosure Act (LDA) |
| EPA FRS id | 110070120473 (REGENERON PHARMACEUTICALS) | name-exact: exact name match to 'REGENERON PHARMACEUTICALS, INC.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110071679215 (REGENERON PHARMACEUTICALS INC) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | EPA ECHO facilities |
| EPA FRS id | 110014446894 (REGENERON PHARMACEUTICALS INC) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | EPA ECHO facilities |
| EPA FRS id | 110000880887 (REGENERON PHARMACEUTICALS INC.) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | EPA ECHO facilities |
| EPA FRS id | 110071845659 (REGENERON PHARMACEUTICALS, INC.) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | EPA ECHO facilities |
| EPA FRS id | 110071067985 (REGENERON PHARMACEUTICALS, INC.) | name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.' | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $14,342,900,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 11:33 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $4,504,900,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 11:33 UTC | Report an error |
| Total assets (at 2025-12-31) | $40,558,700,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 11:33 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $31,256,900,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 11:33 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $3,118,100,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 11:33 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:33 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:33 UTC | Report an error |
| State of incorporation | NY | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:33 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:33 UTC | Report an error |
| Business address | 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:33 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:33 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $4,978,900,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 11:33 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $898,400,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquireProductiveAssets | as filed | 2026-11-21 11:33 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $1,985,900,000 | 2025-12-31 | 10-K, XBRL LongTermDebtNoncurrent | as filed | 2026-11-21 11:33 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $266,800,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 11:33 UTC | Report an error |
| Plan (pension, plan no. 001) | REGENERON PHARMACEUTICALS, INC. 401(K) SAVINGS PLAN: 14,387 participants, assets $3,199,977,583 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 11:33 UTC | Report an error |
| Plan (welfare, plan no. 501) | REGENERON PHARMACEUTICALS, INC. WELFARE BENEFIT PLAN: 11,716 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 11:33 UTC | Report an error |
| Federal award transactions, fiscal year 2026 (this one registration only) | $279,399,579.88 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-21 11:33 UTC | Report an error |
| Number of federal award transactions, fiscal year 2026 (this one registration only) | 15 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-21 11:33 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-30 · accession 0000872589-26-000034
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $5,115,800,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-30 | 0000872589-26-000034 | 2026-11-21 11:33 UTC | Report an error |
| Net income (loss) | $1,948,700,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-30 | 0000872589-26-000034 | 2026-11-21 11:33 UTC | Report an error |
| Interest expense | $10,600,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-30 | 0000872589-26-000034 | 2026-11-21 11:33 UTC | Report an error |
| Cash and cash equivalents | $3,659,100,000 | at 2026-09-30 | 10-Q | 2026-10-30 | 0000872589-26-000034 | 2026-11-21 11:33 UTC | Report an error |
| Contract liabilities, current | $749,800,000 | at 2026-09-30 | 10-Q | 2026-10-30 | 0000872589-26-000034 | 2026-11-21 11:33 UTC | Report an error |
| Contract liabilities, noncurrent | $220,200,000 | at 2026-09-30 | 10-Q | 2026-10-30 | 0000872589-26-000034 | 2026-11-21 11:33 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-19 Filing S-8 filed (FORM S-8)
- 2026-11-05 Filing 13F-HR filed
- 2026-10-30 Filing 10-Q filed
- 2026-10-30 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-13 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-10-06 Filing 8-K filed: Item 1.01 material agreement; Item 2.02 results of operations; Item 8.01 other event
- 2026-10-05 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-09-30 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-20 Filing N-PX filed
- 2026-08-07 Filing 13F-HR filed
- 2026-07-30 Filing 10-Q filed
- 2026-07-30 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-06 Filing 8-K filed: Item 2.02 results of operations
- 2026-06-26 Record latest certified decision date in the file
- 2026-06-17 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-08 Filing 13F-HR filed
- 2026-04-29 Filing 10-Q filed
- 2026-04-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-24 Filing ARS filed
- 2026-04-24 Filing DEFA14A filed (DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS)
- 2026-04-24 Filing DEF 14A filed (DEFINITIVE PROXY STATEMENT)
- 2026-04-08 Filing 8-K filed: Item 2.02 results of operations
- 2026-04-01 Record earliest certified decision date in the file
- 2026-02-06 Filing 13F-HR filed
- 2026-02-04 Filing 10-K filed
9 earlier entries
- 2026-01-30 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-12 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-11-07 Filing 13F-HR filed
- 2025-10-28 Filing 10-Q filed
- 2017-09-28 Contract Contract HHSO100201700016C awarded by Department of Health and Human Services, $973,560,407 obligated to date
- 2017-09-21 Contract Contract HHSO100201700020C awarded by Department of Health and Human Services, $278,844,172 obligated to date
- 2016-08-12 Contract Contract HHSO100201600023C awarded by Department of Health and Human Services, $8,601,629 obligated to date
- 1993-01-01 Record plan effective date: REGENERON PHARMACEUTICALS, INC. 401(K) SAVINGS PLAN
- 1990-01-01 Record plan effective date: REGENERON PHARMACEUTICALS, INC. WELFARE BENEFIT PLAN
8-K item text, as filed (excerpts)
- 2026-10-30 8-K Item 2.02, Results of Operations and Financial Condition
On October 30, 2026, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended September 30, 2026. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall… the 8-K · retrieved 2026-11-21 11:33 UTC - 2026-10-06 8-K Item 1.01, Entry into a Material
Definitive Agreement. On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi, a société anonyme organized under the laws of France (“Sanofi Parent” and, with Sanofi Biotechnology, “Sanofi”), entered into the Sixth Amendment to the Amended and Restated License and Collaboration Agreement (the “Sixth Amendment”), which amends the Amended and Restated License and Collaboration Agreement, dated as of November 10, 2009 (as amended), by and between the Company, Sanofi Biotechnology (as successor in interest to… the 8-K · retrieved 2026-11-21 11:33 UTC - 2026-10-06 8-K Item 2.02, Results of Operations and Financial Condition
Regeneron currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the third quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $22 million on a pre-tax basis. The acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the third quarter 2026 by approximately $0.18. Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as up-front, opt-in, and development milestone payments and premiums paid on equity securities related to… the 8-K · retrieved 2026-11-21 11:33 UTC - 2026-10-06 8-K Item 8.01, Other Events
In connection with the execution of the Sixth Amendment, Regeneron and Sanofi entered into a settlement agreement pursuant to which Regeneron agreed to dismiss its lawsuit concerning Sanofi’s obligation to provide Regeneron with full access to material information relating to the commercialization of Dupixent® (dupilumab) and other products commercialized pursuant to the Antibody LCA, and Regeneron’s audit rights under the Antibody LCA. Note Regarding Forward-Looking Statements This Current Report on Form 8-K (this “Report”) includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results… the 8-K · retrieved 2026-11-21 11:33 UTC - 2026-09-30 8-K Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 1. New Equity Awards for CEO and CSO Effective September 24, 2026 (the “Grant Date”), the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “2026 PSUs”) under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “Equity Plan”) to each of Leonard S.… the 8-K · retrieved 2026-11-21 11:33 UTC - 2026-07-30 8-K Item 2.02, Results of Operations and Financial Condition
On July 30, 2026, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended June 30, 2026. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be… the 8-K · retrieved 2026-11-21 11:33 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
8 lobbying records carry this company's exact name, hiring 7 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (8)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchREGENERON PHARMACEUTICALS INC. (lobbying via CHECKMATE GOVERNMENT RELATIONS) · exact legal name · sx:lda:65271 Compare
- possible matchREGENERON PHARMACEUTICALS, INC (lobbying via REGENERON PHARMACEUTICALS, INC) · exact legal name · sx:lda:200807 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. (lobbying via ARNOLD & PORTER KAYE SCHOLER LLP) · exact legal name · sx:lda:210738 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. (lobbying via BGR GOVERNMENT AFFAIRS) · exact legal name · sx:lda:67618 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. (lobbying via STEWART STRATEGIES AND SOLUTIONS, LLC) · exact legal name · sx:lda:208641 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. (lobbying via THE WASHINGTON TAX & PUBLIC POLICY GROUP) · exact legal name · sx:lda:64079 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. (lobbying via an individual registrant) · exact legal name · sx:lda:196249 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. (lobbying via an individual registrant) · exact legal name · sx:lda:162758 Compare
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (6)
possible match: matched by name only, not merged (6)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchREGENERON PHARMACEUTICALS · exact name match to 'REGENERON PHARMACEUTICALS, INC.' (no other entity shares the name) · sx:epa:110070120473 Compare
- possible matchREGENERON PHARMACEUTICALS INC · exact legal name · sx:epa:110071679215 Compare
- possible matchREGENERON PHARMACEUTICALS INC · exact legal name · sx:epa:110014446894 Compare
- possible matchREGENERON PHARMACEUTICALS INC. · exact legal name · sx:epa:110000880887 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. · exact legal name · sx:epa:110071845659 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. · exact legal name · sx:epa:110071067985 Compare
Breach states (4)
possible match: matched by name only, not merged (4)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchRegeneron Pharmaceuticals · exact name match to 'REGENERON PHARMACEUTICALS, INC.' (no other entity shares the name) · sx:brst:vt:n11420 Compare
- possible matchRegeneron Pharmaceuticals, Inc. · exact legal name · sx:brst:md:ITU-374859-d76e27 Compare
- possible matchRegeneron Pharmaceuticals, Inc. · exact legal name · sx:brst:de:hccb61d6d0946 Compare
- possible matchRegeneron Pharmaceuticals, Inc. (The Lash Group, LLC) · exact legal name · sx:brst:wa:17174 Compare
California data-breach notices (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchRegeneron Pharmaceuticals, Inc. · exact legal name · sx:cabreach:sb24-585823 Compare
DOJ and agency corporate enforcement (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchRegeneron Pharmaceuticals, Inc. · exact legal name · sx:enf:doj:9a9ac1c3-64ec-4551-9309-d94fbf3a8ad6 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $5,682,635,642 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $4,133,919,926 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 3 | Dodge & Cox | $3,037,348,765 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 4 | STATE STREET CORP | $3,014,621,356 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 5 | Invesco Ltd. | $2,457,161,872 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 6 | JPMORGAN CHASE & CO | $2,384,577,378 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | $1,979,934,668 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 8 | FRANKLIN RESOURCES INC | $1,728,352,744 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $1,632,283,060 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
| 10 | Nuveen, LLC | $1,259,533,994 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:33 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
3 legal entities in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- REGENERON INDIA PRIVATE LIMITED · LEI 335800DYBVNUYLGVHJ55
- REGENERON IRELAND DESIGNATED ACTIVITY COMPANY · LEI 635400NABUOXXFAMHX81
- REGENERON PHARMACEUTICALS, INC. · LEI 549300RCBFWIRX3HYQ56 · root
Exhibit 21 subsidiaries: not held yet.
DOL H-1B (LCA) · WARN NOT HELD12. Labor
Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.
WARN layoff notices: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
9 state and city records carry this company's exact name, from 6 sources. Possible matches only.
State licences (4)
possible match: matched by name only, not merged (4)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchREGENERON PHARMACEUTICALS · exact name match to 'REGENERON PHARMACEUTICALS, INC.' (no other entity shares the name) · sx:elic:dcbbl:400323805665 Compare
- possible matchREGENERON PHARMACEUTICALS INC · exact legal name · sx:elic:ctcred:2643627 Compare
- possible matchREGENERON PHARMACEUTICALS INC · exact legal name · sx:elic:ctcred:1041852 Compare
- possible matchREGENERON PHARMACEUTICALS, INC. · exact legal name · sx:elic:ctcred:2535174 Compare
California business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchRegeneron Pharmaceuticals Inc · exact legal name · sx:cabiz:sf:0471116-01-999-0471116 Compare
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchREGENERON PHARMACEUTICALS, INC. · exact legal name · sx:ctsos:1054405 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchRegeneron Pharmaceuticals · exact name match to 'REGENERON PHARMACEUTICALS, INC.' (no other entity shares the name) · sx:ctgov:h940cd02a160ba44c Compare
Eia plants (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchRegeneron Pharmaceuticals Inc. · exact legal name · sx:eia:62423 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchREGENERON PHARMACEUTICALS, INC. · exact legal name · sx:nydos:1226128 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/872589.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000872589. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.